AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Phase 3 trial on Enhertu for HER2-positive metastatic breast cancer showed significant PFS improvement with Enhertu-pertuzumab combo compared to standard care THP. The trial continues with promising interim OS results.